<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2621">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006781</url>
  </required_header>
  <id_info>
    <org_study_id>202002208A0</org_study_id>
    <nct_id>NCT05006781</nct_id>
  </id_info>
  <brief_title>The Dose Finding Study of DAOIB Added to tDCS for AD</brief_title>
  <official_title>The Dose Finding Study of Sodium Benzoate Added to tDCS for the Treatment of Early-phase Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 26-week randomized, double-blind, placebo-controlled trial. We will enroll patients&#xD;
      with aMCI or mild AD. All patients will receive 2 weeks of tDCS (5 sessions per week, 10&#xD;
      sessions in total) during the first 2 weeks of the study, and will also be allocated randomly&#xD;
      to either of 4 treatment groups for 24 weeks: (1) Dose A group; (2) Dose B group; (3) Dose C&#xD;
      group; (4) placebo group. We will assess the patients every 8 weeks during the treatment&#xD;
      period (weeks 0, 10, 18, and 26). We hypothesize that augmentation with certain dose of DAOIB&#xD;
      will yield better effect than tDCS alone in improving the cognitive function, global&#xD;
      functioning and quality of life in patients with aMCI or mild AD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The trial was suspended due to the COVID-19 pandemic&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 1, 2023</start_date>
  <completion_date type="Anticipated">August 19, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 10, 18 and 26</measure>
    <time_frame>week 0, 10, 18, 26</time_frame>
    <description>Alzheimer's disease assessment scale-cognitive subscale scores range from 0 (best) to 70 (worst)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 10, 18 and 26</measure>
    <time_frame>week 10, 18, 26</time_frame>
    <description>Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 10, 18 and 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mini-Mental Status examination score at week 10, 18 and 26</measure>
    <time_frame>week 0, 10, 18, 26</time_frame>
    <description>Change from baseline in Mini-Mental Status examination score at week 10, 18 and 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 10, 18 and 26</measure>
    <time_frame>week 0, 10, 18, 26</time_frame>
    <description>The assessment appears to be a suitable instrument for evaluating activities of daily living in early-phase dementia. Its scores range from 0 (worst) to 78 (best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Quality of life score at week 10, 18 and 26</measure>
    <time_frame>week 0, 10, 18, 26</time_frame>
    <description>Quality of life will be assessed by Medical Outcomes Study Short-Form-36 (SF-36). The SF-36 consists of eight sections: (1) vitality, (2) physical functioning, (3) bodily pain, (4) general health perceptions, (5) physical role functioning, (6) emotional role functioning, (7) social role functioning, and (8) mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the composite score of a battery of additional cognitive tests at week 26</measure>
    <time_frame>week 0, 26</time_frame>
    <description>The battery of additional cognitive tests include speed of processing (Category Fluency), working memory (Wechsler Memory Scale, Spatial Span), verbal/nonverbal learning and memory tests (Wechsler Memory Scale, Word Listing).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Transcranial Direct Current Stimulation</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>tDCS+Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: DAOIB at dose A The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS+Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: DAOIB at dose B The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS+Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: DAOIB at dose C The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS+placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Placebo Device: tDCS tDCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAOIB</intervention_name>
    <description>The DAOIB dose in each group will be fixed during the 24 weeks duration</description>
    <arm_group_label>tDCS+Dose A</arm_group_label>
    <arm_group_label>tDCS+Dose B</arm_group_label>
    <arm_group_label>tDCS+Dose C</arm_group_label>
    <arm_group_label>tDCS+placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Alzheimer's disease or mild cognitive impairment&#xD;
&#xD;
          -  MMSE between 10-26&#xD;
&#xD;
          -  CDR 1 or 0.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hachinski Ischemic Score &gt; 4&#xD;
&#xD;
          -  Substance abuse/dependence&#xD;
&#xD;
          -  Parkinson disease, epilepsy, dementia with psychotic features&#xD;
&#xD;
          -  Major depressive disorder&#xD;
&#xD;
          -  Major physical illnesses&#xD;
&#xD;
          -  Severe visual or hearing impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>October 13, 2022</last_update_submitted>
  <last_update_submitted_qc>October 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

